Follow Us On: Youtube
™
Play Video

Watch ourHair Regeneration Video

A Unique Procedure

RepliCel is developing cell-based therapies to treat hair loss and tendon injuries.

Human Trials in Progress

RepliCel will be initiating Phase II trials on its hair and tendon technologies in late 2013.

Ten Years of Development

RepliCel's autologous cell implantation procedure is based on nine years of development by established research scientists in the fields of immunology, hair biology, hair growth and dermatology.

Patented Proprietary Method

Patents have been accepted in the United States, Australia and the European Union. Additional patent applications, further protecting and expanding our technology are pending in the European Union, Canada, Japan the United States, as well as other countries.

Growing Market

The worldwide market for surgical hair restoration is estimated at US $1.2 billion annually by the International Society of Hair Restoration Surgery. The American Academy of Family Physicians estimates the US market for non-surgical hair loss treatments at over US $1 billion annually.

News & Events

May 21, 2013

RepliCel Announces Closing of Private Placement

May 3, 2013

RepliCel’s Chief Scientific Officer Updates World Congress for Hair Research on 12-Month Safety Data from its Phase I Clinical Trial

April 30, 2013

RepliCel Announces New Tendon Repair Technology Based on its Hair Follicle Cellular Expertise

A new course of action:
Developing Autologous Cell Therapies

RepliCel Life Sciences Inc. specializes in autologous cell therapy technologies. The company's foundation is built on its core understanding of the unique biological function of hair follicle cells.

From that knowledge platform, the company has developed two separate autologous cell therapies. The first is a cellular treatment for androgenetic alopecia (pattern baldness) named RepliCel Hair-01 ("RCH-01"). The second is a cell therapy treatment for chronic tendon injuries named RepliCel Tendon-01 ("RCT-01"). Both treatments are based on RepliCel's innovative technology which utilizes cells isolated from a patient's own healthy hair follicles to address specific cellular deficits associated with the targeted conditions.

RepliCel's RCH-01 Phase II dose-ranging trial of approximately 120 subjects is targeted for the second half of 2013 and will run through 2015. The trial will be conducted in Germany.

RepliCel's RCT-01 Phase II Achilles tendinosis trial of approximately 90-120 subjects is targeted for late 2013 and will run for 12 months.

Close